<DOC>
	<DOCNO>NCT01275157</DOCNO>
	<brief_summary>This single dose study radiolabeled [ 14C ] -LY2452473 healthy male volunteer study absorption , distribution , metabolism , elimination LY2452473 . This study research purpose intend treat medical condition .</brief_summary>
	<brief_title>Disposition 14C-LY2452473 Following Oral Administration Healthy Human Subjects</brief_title>
	<detailed_description />
	<criteria>Experience average 1 2 bowel movement per day Overtly healthy male , determine medical history physical examination Subjects either sterile , sexually active , agree use reliable method birth control checkin 3 month followup assessment Are body mass index ( BMI ) 19 29 kg^m2 , inclusive Clinical laboratory test result within normal reference range clinical research unit laboratory result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample Normal blood pressure pulse rate ( sit ) determine investigator Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly Institutional Review Board ( IRB ) govern site Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device study drug use study , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2452473 relate compound Within 30 day initial dose study drug , receive treatment drug receive regulatory approval indication Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , psychiatric , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication interfere interpretation data Have condition opinion investigator would preclude participation study Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Intended use overthecounter herbal medication within 7 day prescription medication within 14 day prior dose Have donate 500 mL blood within last month Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption duration study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Use herbal preparation contain St. John 's Wort , kava , garlic , ginger , gingko biloba , guarana within 14 day prior admission Consumption grapefruit grapefruitcontaining food juice within 7 day prior dose time study Heavy caffeine drinker define regular intake 5 cup ( 4050 mg caffeine per cup ) coffee ( equivalent xanthinecontaining beverage ) per day caffeine drinking subject consistent daily caffeine consumption 1 month prior study entry subject willing maintain consistent caffeine consumption study Have participate [ 14C ] study within last 12 month . The previous radiolabeled study drug must receive 6 month prior Checkin study cumulative annual radiation exposure must consistent Food Drug Administration ( FDA ) recommendation , example whole body exposure le 5,000 mrem/year Exposure significant radiation within 12 month prior dose ( example , serial Xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Absorption</keyword>
	<keyword>Distribution</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
	<keyword>Mass balance</keyword>
	<keyword>Metabolic profile</keyword>
	<keyword>Radiolabeled study</keyword>
	<keyword>14C</keyword>
</DOC>